<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873767</url>
  </required_header>
  <id_info>
    <org_study_id>UP0028</org_study_id>
    <secondary_id>2016-000772-26</secondary_id>
    <nct_id>NCT02873767</nct_id>
  </id_info>
  <brief_title>A First-In-Human Study With a Single Dose UCB4019 in Healthy Volunteers</brief_title>
  <official_title>A Subject-Blind, Investigator-Blind, Randomized, Placebo-Controlled, First-In-Human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of UCB4019 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and tolerability of single ascending doses of
      UCB4019 administered by subcutaneous injection in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events during the study</measure>
    <time_frame>Day 1 up to Day 57</time_frame>
    <description>An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Pharmacokinetic samples will be taken predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose and Days 7, 10, 13, 16, 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 to time t, the time of last quantifiable concentration [(AUC0-t)]</measure>
    <time_frame>Pharmacokinetic samples will be taken predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose and Days 7, 10, 13, 16, 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Pharmacokinetic samples will be taken predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose and Days 7, 10, 13, 16, 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in total Immunoglobulin G (IgG) concentration at day 7</measure>
    <time_frame>Predose (Day 1), Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in total Immunoglobulin G (IgG) concentration at day 10</measure>
    <time_frame>Predose (Day 1), Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in total Immunoglobulin G (IgG) concentration at day 13</measure>
    <time_frame>Predose (Day 1), Day 13</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose placebo comparator for each active arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB4019 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 calculated based on body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB4019 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 calculated based on body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB4019 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 calculated based on body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB4019 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 calculated based on body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR1</intervention_name>
    <description>Active substance: UCB4019
Route of Administration: subcutaneously</description>
    <arm_group_label>UCB4019 Dose 1</arm_group_label>
    <arm_group_label>UCB4019 Dose 2</arm_group_label>
    <arm_group_label>UCB4019 Dose 3</arm_group_label>
    <arm_group_label>UCB4019 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PL1</intervention_name>
    <description>Active substance: Placebo
Concentration: 0.9 % saline
Route of Administration: subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good physical and mental health

          -  At least 18 and less than 65 years of age

          -  Female subjects of childbearing potential must agree to use a highly effective method
             of birth control, during the study and for a period of 3 months after their last dose
             of study drug

        Exclusion Criteria:

          -  Total Immunoglobulin G &lt;7 g/L or &gt;16 g/L at the Screening Visit

          -  Absolute neutrophil count &lt;1.5x10^9/L and/or lymphocyte count &lt;1.0x10^9/L

          -  Known viral hepatitis, has a positive test for Hepatitis B surface antigen or is
             Hepatitis C virus antibody positive

          -  Positive test to Human Immunodeficiency Virus (HIV) 1/2 antibodies

          -  Past medical history or family history of primary immunodeficiency

          -  Evidence of latent/active Tuberculosis (TB)

          -  Active infection or a serious infection within 6 weeks before the first dose of IMP

          -  Renal impairment

          -  Hepatic impairment

          -  Vaccination within 6 weeks before the Screening Visit or intent to have a vaccination
             before Day 43 of the Safety Follow-up Period

          -  Subject is splenectomized

          -  received any IMP or experimental procedure within 90 days before the first dose of IMP

          -  received UCB7665 in a clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>UCB (+1 887 822 9493)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up0028 001</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in human</keyword>
  <keyword>Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

